期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

鲁索利替尼的药理与临床研究 被引量：3

Pharmacological and clinical study of ruxolitinib
原文传递
导出
摘要 鲁索利替尼为一种可口服给药的选择性JAK1/JAK2激酶抑制剂,是首个被美国FDA批准用于骨髓纤维化治疗的药物。本文通过文献检索,对其药理作用、药动学、药物相互作用、临床研究和安全性进行了综述。 Ruxolitinib is an orally available, selective inhibitor for Janus kinase （JAK） 1 and 2. Ruxolitinib is the first US Food and Drug Administration approved therapy for the treatment of myelofibrosis. A literature search was conducted using MEDLINE with the key words ruxolitinib. The pharmacology, pharmacokinetics, drug interactions, clinical study and safety of ruxolitinib was reviewed in this paper.
作者 孙搏 高君伟 李晓宇 刘皋林
机构地区 上海交通大学附属第一人民医院药学部
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第11期1233-1235,1241,共4页 Chinese Journal of New Drugs
关键词 鲁索利替尼 骨髓纤维化 药理作用 临床研究 ruxolitinib myelofibrosis pharmacology clinical study
分类号 R979.5 [医药卫生—药品]
  • 相关文献

参考文献10

  • 1QUINTAS-CARDAMA A, VADDI K, LIU P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms[J]. Blood, 2010, 115(15):3109-3117.
  • 2SHI JG, CHEN X, MCGEE RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers [ J]. J Clin Pharmacol, 2011, 51(12) :1644 - 1654.
  • 3VERSTOVSEK S, KANTARJIAN H, MESA RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis[J]. NEnglJMed,2010, 363(12) :1117-1127.
  • 4JAKAF (ruxolitinib) prescribing information. Incyte Corp; Wihnington, DE :2011.
  • 5TEFFERI A, LITZOW MR, PARDANANI A. Long-term outcome of treatment with ruxolitinib in myelofibrosis [ J ]. N Engl J Med, 2011, 365(15) :1455 - 1457.
  • 6VERSTOVSEK S, KANTARJIAN HM, ESTROV Z, et al. Long- term outcomes of 107 patients with myelofibrosis receiving JAKI/ JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls[ J]. Blood,2012,120(6):1202- 1209.
  • 7VERSTOVSEK S, MESA RA, GOTLIB J, et al. A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis [J]. NEnglJMed, 2012, 366(9) :799 -807.
  • 8HARRISON C, KILADJIAN JJ, AL-ALI HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis [J]. NEnglJMed, 2012, 366(9):787-798.
  • 9EGHTEDAR AVS, CORTES JE, ESTROV Z, et al. Phase II study of the JAK2 inhibitor, INCB018424, in patients with refractory leukemias including post-myeloproliferative disorder (MPD) acute myeloid leukemia (sAML) [ J]. ASH Annual Meeting Abstracts ,2011 , 116:509.
  • 10SHI JG, CHEN X, EMM T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib ( INCB018424 Phosphate) in healthy volunteers[J]. J Clin Pharmacol,2012, 52(6) :809 -818.

同被引文献23

引证文献3

二级引证文献3

中国新药杂志
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部